In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion. If they combine, Mylan and Perrigo would become one of the world's largest makers of generic and over-the-counter medicines. Mylan said the combined company would have had $15.3 billion in revenue in 2014 and would also be a leader in specialty drugs and nutritional products. It said the combined company would be able to grow even further with additional acquisitions. Mylan says it delivered a proposal to Perrigo on Monday. Perrigo confirmed that it received the offer and said its board will discuss the proposal. Mylan said it wants the combined company led by Mylan executives including Chairman Robert Coury and CEO Heather Bresch. Mylan NV's best-selling product is the EpiPen Auto Injector, an emergency treatment for allergic reactions made by Pfizer. Mylan reported $1.19 billion in revenue from EpiPen in 2014 and the company says EpiPen is its first product to reach $1 billion in annual sales.